Barrett's esophagus (BE) is a rapidly increasing preneoplastic disorder that arises in the setting of chronic inflammation and repeated injury from acid and bile reflux. While the histopathologic progression of BE to EAC has been well characterized, the cell of origin for BE has been poorly understood. Recent studies have focused on the possibility of transdifferentiation of squamous epitheilial progenitors, but work from our group has pointed to progenitors that reside in the gastric cardia. Using a newly created L2-IL-1beta transgenic mouse model of BE/EAC, in which IL-1 beta is over expressed in the esophageal squamous mucosa, we have observed an early upregulation of progenitors expressing Lgr5, Cck2r, and Dclkl in the proximal stomach just below the squamocolumnar junction (SCJ). These progenitors, which are absent in normal esophageal squamous mucosa, are amplified first in the gastric cardia by inflammation and bile acids, and migrate over time proximally into the SCJ in association with expansion of BE. These progenitors are also absent from normal human squamous esophageal epithelium but markedly upregulated in human Barrett's. Preliminary studies by our group using inducible Cre-ERT2 mice have shown that Lgr5 and Cck2r mark active stem or progenitor cells In the cardia, while Dclkl marks a long-lived quiescent stem cell in the gastric cardia. Based on these studies, we propose three specific aims: (1) What is the role of active (Lgr5+ or Cck2r+) stenri/progenitor cells present in the cardia in the development of Barrett's esophagus in the mouse? Lineage tracing studies of Lgr5+ and Cck2r+ progenitors will be performed in the normal gastic cardia, in the BE/EAC lesions in the L2-lL-1b mouse, and in the surgical reflux (esophagojejunostomy) model of BE. (2), What is the role of quiescent (Dclkl) stem cells present in the cardia in the development of BE in the mouse? Both constitutive and inducible lines of Dclkl-Cre mice will be used in lineage tracing studies, and the relationship to other progenitors explored, (3). Does administration of YF476 (a Cck2r-specific antagonist) to human patients with BE inhibit cellular proliferation? We will carry out a pilot clinical trial to determine if targeting cardia progenitors early on may represent a potential chemoprevention strategy.

Public Health Relevance

This study is an attempt at lineage tracing of progenitors in a murine model of Barrett's esophagus in order to establish the cellular origins of the disorder. In addition, we will attempt to target these cardia progenitors using an antagonist specific to receptors present on these cells. We hypothesize that inhibiting receptors expressed by gastric cardia sterp cells may represent a potential strategy to prevent BE progression.

Agency
National Institute of Health (NIH)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163004-04
Application #
8731832
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10019
Abrams, Julian A; Appelman, Henry D; Beer, David G et al. (2014) Barrett's Esophagus Translational Research Network (BETRNet): the pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research. Gastroenterology 146:1586-90
Fudman, David I; Lightdale, Charles J; Poneros, John M et al. (2014) Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. Gastrointest Endosc 80:71-7
Freedberg, Daniel E; Abrams, Julian A; Wang, Timothy C (2014) Prevention of gastric cancer with antibiotics: can it be done without eradicating Helicobacter pylori? J Natl Cancer Inst 106:
Hartman, Kira G; Bortner Jr, James D; Falk, Gary W et al. (2014) Modeling human gastrointestinal inflammatory diseases using microphysiological culture systems. Exp Biol Med (Maywood) 239:1108-23
Timmer, M R; Sun, G; Gorospe, E C et al. (2013) Predictive biomarkers for Barrett's esophagus: so near and yet so far. Dis Esophagus 26:574-81
Gupta, Milli; Iyer, Prasad G; Lutzke, Lori et al. (2013) Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology 145:79-86.e1
Tomizawa, Yutaka; Iyer, Prasad G; Wong Kee Song, Louis M et al. (2013) Safety of endoscopic mucosal resection for Barrett's esophagus. Am J Gastroenterol 108:1440-7; quiz 1448
Wang, Kenneth K (2013) The essence of management of Barrett's esophagus. Gastrointest Endosc 78:702-3
Quante, Michael; Abrams, Julian A; Wang, Timothy C (2013) The rapid rise in gastroesophageal junction tumors: is inflammation of the gastric cardia the underwater iceberg? Gastroenterology 145:708-11
Leggett, Cadman L; Gorospe, Emmanuel C; Wang, Kenneth K (2013) Endoscopic therapy for Barrett's esophagus and early esophageal adenocarcinoma. Gastroenterol Clin North Am 42:175-85

Showing the most recent 10 out of 13 publications